Dietary Supplements and Diets Show No Impact on Cardiovascular Risk

Americans spend billions in dietary supplements every year but, in truth, this money is only wasted, according to evidence form a recent study published in Intern Med.

Nuevas alternativas prometedoras para la insuficiencia mitral

Most of dietary interventions and nutritional supplements including multi-vitamins, selenium and antioxidants, do not reduce cardiovascular risk or mortality, according to this large analysis and systematic revision of several randomized studies.

Modest benefits were indeed observed when reducing salt consumption and when incorporating omega 3 polyunsaturated fatty acids and folic acid.

On the other hand, combining calcium and vitamin D seems to increase stroke risk.

However, despite different guidelines and societies claim the evidence behind these recommendations is insufficient, one every other American consume some sort of vitamin or dietary supplement, and the proportion increases with age.


Read also: Supervised Exercise and Revascularization for Intermittent Claudication.


In this context, researchers wanted to provide quality evidence by testing the effect of nutritional supplements and, to this end, included 9 systematic reviews and 4 randomized studies with nearly one million participants. Data included studies VITAL and ASCEND, which studied the impact of vitamin D and omega-3.

Globally, they were able to find certain evidence that reduced salt consumption has a modest positive effect on global mortality in persons with normal blood pressure (RR 0.90; 95% CI 0.85-0.95) and a more significant positive effect on cardiovascular mortality in hypertensives (RR 0.67; 95% CI 0.46-0.99).

Additionally, “low certainty” evidence suggested omega-3 acids reduce the risk of infarction and heart disease.

There was also “low certainty” evidence that folic acid reduced stroke risk, though this benefit was driven basically by one single study conducted in China.


Read also: Many Guidelines, Much Confusion. Blood Pressure Targets in the Elderly.


Finally, and with “moderate certainty”, calcium and vitamin D supplements would increase stroke risk (RR 1.17; 95% CI 1.05-1.30).

No other supplement, including vitamins A, B complex, C, D or E, antioxidants, iron or other dietary interventions (including reduced fat intake) impact mortality or cardiovascular events, neither positively nor negatively.

Most people are wasting their money in vitamins, buying supplements at the pharmacy, when it would be more sensible, rational and a lot cheaper to buy vitamins at the groceries’.

Most surprisingly, the “Mediterranean diet” showed no impact, seeing as the PREDIMED outcomes suggest the benefit of diets rich in vegetables, whole grains, nuts and olive oil. Researchers speculate these results might have been counterbalanced with other study results with null outcomes.

Original title: Effects of nutritional supplements and dietary interventions on cardiovascular outcomes: an umbrella review and evidence map.

Reference: Khan SU et al. Ann Intern Med. 2019;171:190-198.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...